Day: February 3, 2021

Opgørelsen er baseret på samme regnskabspraksis som årsrapporten for 2019.Opgørelsen er ikke revideret. Der tages forbehold for endelig opgørelse.Med venlig hilsenStrategic Investments A/SVedhæftet filSI_02_2021_NAV310121

Følsomheden på den indre værdi af aktier i SmallCap Danmark A/S overfor ændringer i børskursen på aktier i Rias A/S er d.d.:Opgørelsen er baseret på samme regnskabspraksis som årsrapporten for 2019.Opgørelsen er ikke revideret. Der tages forbehold for endelig opgørelse.Med venlig hilsenSmallCap Danmark A/SVedhæftet filAS_03_2021_NAV310121

NEW YORK and LONDON, Feb. 03, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) (“Tiziana” or the “Company“), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO and CSO, is now available.In the exclusive interview, Dr. Shailubhai discusses the positive effect of nasally administered Foralumab in COVID-19 mediated pulmonary and systemic inflammation and its potential related to newly identified COVID-19 variants in UK, South Africa, and Brazil. Dr. Shailubhai also comments on the nearly 2x improvement shown in CT scans of the lungs of patients treated with Foralumab as compared to those in the control group.COVID-19 enters through the nasal and respiratory passage,...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST).Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in...

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Galantas Gold Corporation (the “Company” or “Galantas”), the Northern Ireland gold producer and explorer, with a 100% interest in Northern Ireland’s Omagh gold mine, is pleased to announce that a formal agreement regarding blasting has been reached between the Company’s operating subsidiary and the Police Service of Northern Ireland (PSNI). The PSNI have responsibilities regarding the supervision of the use of blasting materials in Northern Ireland.The agreement provides the potential for a materially improved economic arrangement for an expansion of underground blasting, required for full production, to take place at the Omagh Mine. The agreement has followed a comprehensive review by the PSNI and regulators.Roland Phelps, (President & CEO, Galantas Gold Corporation), said, “The agreement...

Le recrutement des patients pour la Partie 2 de l’Étude COVA va démarrer dans la plupart des centres d’essais cliniques au Brésil et aux États-UnisL’analyse intermédiaire de la Partie 1 est attendue au cours du premier trimestre 2021Les résultats de l‘étude complète (Parties 1 et 2) sont attendus au cours du deuxième trimestre 2021PARIS et CAMBRIDGE, Mass., 03 févr. 2021 (GLOBE NEWSWIRE) — Biophytis SA (Euronext Growth Paris : ALBPS), société de biotechnologie au stade clinique, spécialisée dans le développement de traitements qui ralentissent les processus dégénératifs liés au vieillissement et qui améliorent les résultats fonctionnels des patients souffrant de maladies liées à l’âge, y compris l’insuffisance respiratoire sévère chez les patients souffrant de la COVID-19, annonce aujourd’hui que le recrutement...

Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United StatesInterim Analysis of Part 1 is expected in Q1 2021Results from the full study (Part 1 and Part 2) are expected in Q2 2021PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute...

PARIS et CAMBRIDGE, Mass., 03 févr. 2021 (GLOBE NEWSWIRE) — BIOPHYTIS SA (Euronext Growth Paris : ALBPS), société de biotechnologie au stade clinique, spécialisée dans le développement de traitements qui ralentissent les processus dégénératifs liés au vieillissement et qui améliorent les résultats fonctionnels des patients souffrant de maladies liées à l’âge, y compris l’insuffisance respiratoire chez les patients souffrant de la COVID-19, annonce aujourd’hui, sous réserve des conditions de marché et d’autres conditions, son intention d’offrir et de vendre jusqu’à 12 millions d’actions ordinaires nouvelles sous la forme de 1,2 millions d’American Depositary Shares (« ADSs »), chacune d’entre elles représentant dix actions ordinaires, aux États-Unis (l’ « Offre ADS »).H.C. Wainwright & Co. agit en qualité de teneur...

PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) — Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces its intention to offer and sell, subject to market and other conditions, up to 12.0 million ordinary shares represented by 1.2 million American Depositary Shares (the “ADSs”), with each ADS representing ten ordinary shares, in the United States (the “ADS Offering”).H.C. Wainwright & Co. is acting as sole book-running manager for the ADS Offering.Biophytis intends to grant to H.C. Wainwright...

Hexagon Composites ASA’s fourth quarter and preliminary annual 2020 results will be released on 17 February 2021, 07:00 CET.Jon Erik Engeset (CEO) and David Bandele (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live. The presentation will be held in English.Link to webcast: https://hexagongroup.kg5.no/A recording of the presentation will be made available on www.hexagongroup.com after the presentation.Hexagon Purus (HPUR), which is part of Hexagon Composites ASA, will present its Q4 and preliminary annual 2020 results on 16 February 2021.For more information:Hiva Ghiri, Vice President Investor Relations, Hexagon Composites ASATelephone: +47 958 66 790 | hiva.ghiri@hexagongroup.comAbout Hexagon Composites ASAHexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions...